NASDAQ:UPB

Upstream Bio Q1 2025 Earnings Results & Report

Upstream Bio logo
$2.00 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+0.75%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Upstream Bio missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.51 versus the -$0.49 consensus estimate, while revenue of $570 thousand fell short of the $710 thousand estimate by $140 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Upstream Bio EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Upstream Bio Revenue Results

Actual Revenue
$570 thousand
Expected Revenue
$710 thousand
Beat/Miss
Missed by -$140.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Q1 2025 Earnings FAQ

Upstream Bio (NASDAQ:UPB) reported earnings of -$0.51 per share for Q1 2025, missing the consensus estimate of -$0.49. The report was announced on Tuesday, May 6, 2025.

Upstream Bio reported revenue of $570 thousand for Q1 2025, against a consensus estimate of $710 thousand.

Upstream Bio Earnings Headlines

HC Wainwright Increases Earnings Estimates for Upstream Bio
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB) is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses.

Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.

The company’s work is focused on drug development and clinical research; it does not have a marketed product portfolio.

View Upstream Bio Profile